65,437 trials
Rheumatoid Arthritis
Primary: Change From Baseline in Small Low Density Lipoprotein (sLDL) Particle Numbers — 737.79; 792.78; 768.04; 777.71 nmol/L
Ischemic Stroke
Primary: Percent of Participants With National Institutes of Health Stroke Scale (NIHSS) Score = 0 or 1 at Day 90 — 69; 33; 0; 45 percentage of participants
Carcinoma, Non-small Cell Lung
Primary: Response Rate Defined as the Percentage of Subjects Achieving at Least 50% Tumor Volume Reduction. — 1 Participants — p=<0.01
Lung Cancer
Primary: Overall Response Rate — 26 Percentage of participants
Lung Cancer
Primary: Pathologic Complete Response Rate — 0 Percentage of participants
Leukoplakia · Erythroplakia
Primary: Maximum Tolerated Dose — 8 J/cm2
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Lung Cancer
Primary: Overall Clinical Response Rate — 17 Percentage of participants
Myopia · Astigmatism · Refractive Error
Primary: Change From Baseline (Day 0) in Ocular Comfort Rating at Day 14 — 87.40; 88.79; 81.75; 83.18 Units on a scale
Essential Hypertension
Primary: Percentage of Participants With at Least 1 Adverse Event — 78.5; 76.4 percentage of participants
Healthy Subjects
Primary: Changes in Histamine-induced Wheal Size — 14.9; 14.9; 14.1; 16.5 mm^2
Nasolacrimal Duct Obstruction
Primary: Proportion of Participants With Treatment Success — 0.92; 0.82 proportion of participants — p=0.09
Dilated Cardiomyopathy
Primary: Aortic Velocity Time Integral (VTI) — 22.4; 21.7; 19.4; 18.1 cm
Chronic Obstructive Pulmonary Disease, COPD
Primary: Forced Expiratory Volume in 1 Second (FEV1) Pre-dose — 0.064; -0.001 Liters
Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: Visual Analog Scale (VAS) — 7.47; 7.97 units on a scale